Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5845-5851
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5845
Figure 2
Figure 2 Patient serum withdrawn before anti-tumor necrosis factor-α therapy induced (A) forkhead transcription factor 3 (r = -0. 600, P = 0.018) and (B) glucocorticoid-induced tumour necrosis factor receptor (r = -0.589, P = 0.021) specific mRNA expression (relative units) in activated target cells that had a negative correlation with the change of Crohn’s disease endoscopic index of severity during three months therapy. The change of Crohn’s disease endoscopic index of severity (CDEIS) corresponds with the decrease in points along improvement and is given as a positive value to illustrate the magnitude of therapeutic response. Patients who showed no decrease in the CDEIS during therapy are marked with star. GITR: Glucocorticoid-induced tumour necrosis factor receptor; FOXP3: Forkhead transcription factor 3.